Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Multiantigenic Nanotoxoids for Antivirulence Vaccination against Antibiotic-Resistant Gram-Negative Bacteria.

Wei X, Ran D, Campeau A, Xiao C, Zhou J, Dehaini D, Jiang Y, Kroll AV, Zhang Q, Gao W, Gonzalez DJ, Fang RH, Zhang L.

Nano Lett. 2019 Jul 10;19(7):4760-4769. doi: 10.1021/acs.nanolett.9b01844. Epub 2019 Jun 11.

PMID:
31184899
2.

In Situ Capture of Bacterial Toxins for Antivirulence Vaccination.

Wei X, Gao J, Wang F, Ying M, Angsantikul P, Kroll AV, Zhou J, Gao W, Lu W, Fang RH, Zhang L.

Adv Mater. 2017 Sep;29(33). doi: 10.1002/adma.201701644. Epub 2017 Jun 28.

3.

Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles.

Angsantikul P, Fang RH, Zhang L.

Bioconjug Chem. 2018 Mar 21;29(3):604-612. doi: 10.1021/acs.bioconjchem.7b00692. Epub 2017 Dec 27. Review.

4.

Nanoparticle-Based Antivirulence Vaccine for the Management of Methicillin-Resistant Staphylococcus aureus Skin Infection.

Wang F, Fang RH, Luk BT, Hu CJ, Thamphiwatana S, Dehaini D, Angsantikul P, Kroll AV, Pang Z, Gao W, Lu W, Zhang L.

Adv Funct Mater. 2016 Mar 8;26(10):1628-1635. Epub 2016 Feb 5.

5.

Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice.

Zhang X, Yang F, Zou J, Wu W, Jing H, Gou Q, Li H, Gu J, Zou Q, Zhang J.

Vaccine. 2018 Feb 14;36(8):1047-1054. doi: 10.1016/j.vaccine.2018.01.034.

PMID:
29406241
6.

Battacin (Octapeptin B5), a new cyclic lipopeptide antibiotic from Paenibacillus tianmuensis active against multidrug-resistant Gram-negative bacteria.

Qian CD, Wu XC, Teng Y, Zhao WP, Li O, Fang SG, Huang ZH, Gao HC.

Antimicrob Agents Chemother. 2012 Mar;56(3):1458-65. doi: 10.1128/AAC.05580-11. Epub 2011 Dec 19.

7.

Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.

Kaye KS, Pogue JM.

Pharmacotherapy. 2015 Oct;35(10):949-62. doi: 10.1002/phar.1636. Review.

PMID:
26497481
8.

Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.

Chiuppesi F, Nguyen J, Park S, Contreras H, Kha M, Meng Z, Kaltcheva T, Iniguez A, Martinez J, La Rosa C, Wussow F, Diamond DJ.

J Virol. 2018 Sep 12;92(19). pii: e01012-18. doi: 10.1128/JVI.01012-18. Print 2018 Oct 1.

9.

Protection against Staphylococcus aureus Colonization and Infection by B- and T-Cell-Mediated Mechanisms.

Zhang F, Ledue O, Jun M, Goulart C, Malley R, Lu YJ.

MBio. 2018 Oct 16;9(5). pii: e01949-18. doi: 10.1128/mBio.01949-18.

10.

Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.

Wu W, Huang J, Duan B, Traficante DC, Hong H, Risech M, Lory S, Priebe GP.

Am J Respir Crit Care Med. 2012 Sep 1;186(5):420-7. doi: 10.1164/rccm.201202-0182OC. Epub 2012 Jun 21.

11.

Membrane Vesicles Derived from Bordetella bronchiseptica: Active Constituent of a New Vaccine against Infections Caused by This Pathogen.

Bottero D, Zurita ME, Gaillard ME, Bartel E, Vercellini C, Hozbor D.

Appl Environ Microbiol. 2018 Jan 31;84(4). pii: e01877-17. doi: 10.1128/AEM.01877-17. Print 2018 Feb 15.

12.

Engineered endolysin-based "Artilysins" to combat multidrug-resistant gram-negative pathogens.

Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A, Oliveira H, Azeredo J, Verween G, Pirnay JP, Miller S, Volckaert G, Lavigne R.

MBio. 2014 Jul 1;5(4):e01379-14. doi: 10.1128/mBio.01379-14.

13.

A Live Salmonella Vaccine Delivering PcrV through the Type III Secretion System Protects against Pseudomonas aeruginosa.

Aguilera-Herce J, García-Quintanilla M, Romero-Flores R, McConnell MJ, Ramos-Morales F.

mSphere. 2019 Apr 17;4(2). pii: e00116-19. doi: 10.1128/mSphere.00116-19.

14.

Hydrogen peroxide-inactivated bacteria induces potent humoral and cellular immune responses and releases nucleic acids.

Fan Y, Mu Y, Lu L, Tian Y, Yuan F, Zhou B, Yu C, Wang Z, Li X, Lei S, Xu Y, Wu D, Yang L.

Int Immunopharmacol. 2019 Apr;69:389-397. doi: 10.1016/j.intimp.2019.01.055. Epub 2019 Feb 16.

PMID:
30780019
15.

Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity.

Kroll AV, Fang RH, Jiang Y, Zhou J, Wei X, Yu CL, Gao J, Luk BT, Dehaini D, Gao W, Zhang L.

Adv Mater. 2017 Dec;29(47). doi: 10.1002/adma.201703969. Epub 2017 Nov 2.

16.

New Mouse Model for Chronic Infections by Gram-Negative Bacteria Enabling the Study of Anti-Infective Efficacy and Host-Microbe Interactions.

Pletzer D, Mansour SC, Wuerth K, Rahanjam N, Hancock RE.

MBio. 2017 Feb 28;8(1). pii: e00140-17. doi: 10.1128/mBio.00140-17.

17.

Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections.

Meynet E, Laurin D, Lenormand JL, Camara B, Toussaint B, Le Gouëllec A.

Vaccine. 2018 Mar 27;36(14):1893-1900. doi: 10.1016/j.vaccine.2018.02.040. Epub 2018 Mar 2.

PMID:
29506924
18.

Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.

Lemaître N, Liang X, Najeeb J, Lee CJ, Titecat M, Leteurtre E, Simonet M, Toone EJ, Zhou P, Sebbane F.

MBio. 2017 Jul 25;8(4). pii: e00674-17. doi: 10.1128/mBio.00674-17.

19.

Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.

Kamei A, Coutinho-Sledge YS, Goldberg JB, Priebe GP, Pier GB.

Infect Immun. 2011 Mar;79(3):1289-99. doi: 10.1128/IAI.01139-10. Epub 2010 Dec 13.

20.

Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial.

Giammanco A, Calà C, Fasciana T, Dowzicky MJ.

mSphere. 2017 Jan 18;2(1). pii: e00310-16. doi: 10.1128/mSphere.00310-16. eCollection 2017 Jan-Feb.

Supplemental Content

Support Center